Elahe Sadat Hejazi
Overview
Explore the profile of Elahe Sadat Hejazi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirzaei S, Paskeh M, Moghadam F, Entezari M, Koohpar Z, Hejazi E, et al.
J Cell Commun Signal
. 2023 Nov;
17(4):1181-1202.
PMID: 38019354
The treatment of cancer patients has been prohibited by chemoresistance. Doxorubicin (DOX) is an anti-tumor compound disrupting proliferation and triggering cell cycle arrest via inhibiting activity of topoisomerase I and...
2.
Entezari M, Paskeh M, Orouei S, Kakavand A, Rezaei S, Hejazi E, et al.
Curr Cancer Drug Targets
. 2023 Apr;
PMID: 37069720
The capacity of cancer cells for abnormal growth and metastasis has made it difficult to find a cure for tumor. Both males and females suffer from lung tumors, and physicians...
3.
Entezari M, Taheriazam A, Paskeh M, Sabouni E, Zandieh M, Aboutalebi M, et al.
Biomed Pharmacother
. 2023 Feb;
160:114313.
PMID: 36738498
Up to 18% of cancer-related deaths worldwide are attributed to lung tumor and global burden of this type of cancer is ascending. Different factors are responsible for development of lung...
4.
Mirzaei S, Paskeh M, Entezari M, Bidooki S, Ghaleh V, Rezaei S, et al.
Clin Transl Oncol
. 2022 Dec;
25(5):1167-1188.
PMID: 36562927
Recently, nucleic acid drugs have been considered as promising candidates in treatment of various diseases, especially cancer. Because of developing resistance to conventional chemotherapy, use of genetic tools in cancer...
5.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, et al.
J Cell Commun Signal
. 2022 Nov;
17(3):423-443.
PMID: 36367667
Urological cancers have obtained much attention in recent years due to their mortality and morbidity. The most common and malignant tumor of urological cancers is prostate cancer that imposes high...
6.
Mirzaei S, Paskeh M, Entezari M, Mirmazloomi S, Hassanpoor A, Aboutalebi M, et al.
Biomed Pharmacother
. 2022 Oct;
156:113860.
PMID: 36272267
Cancer is a leading cause of death worldwide and around 10 million deaths in 2020 were related to cancer. There are a number of therapeutic modalities for cancer such as...
7.
Hashemi M, Mirzaei S, Barati M, Hejazi E, Kakavand A, Entezari M, et al.
Life Sci
. 2022 Sep;
309:120984.
PMID: 36150461
Urological cancers include bladder, prostate and renal cancers that can cause death in males and females. Patients with urological cancers are mainly diagnosed at an advanced disease stage when they...
8.
Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi E, et al.
Biomed Pharmacother
. 2022 Aug;
154:113609.
PMID: 36037786
Epigenetic factors are critical regulators of biological and pathological mechanisms and they could interact with different molecular pathways. Targeting epigenetic factors has been an idea approach in disease therapy, especially...
9.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, et al.
Pharmacol Res
. 2022 Jun;
182:106311.
PMID: 35716914
Epithelial-to-mesenchymal transition (EMT) mechanism is responsible for metastasis of tumor cells and their spread to various organs and tissues of body, providing undesirable prognosis. In addition to migration, EMT increases...